改良型TAT-VP3融合蛋白对膀胱癌的抑制效应研究

Inhibitory effect of modified type TAT-VP3 fusion protein on bladder cancer

目的探讨改良型TAT-VP3融合蛋白对膀胱癌细胞的抑制效应,为其临床应用于肿瘤的生物大分子药物治疗提供实验基础。方法运用免疫细胞化学染色法确定改良型TAT-VP3融合蛋白进入到膀胱癌细胞EJ的细胞核内,CCK-8检测EJ细胞的生长抑制率,通过透射电镜观察凋亡细胞的超微结构变化,流式细胞术检测细胞周期和细胞凋亡率。结果改良型TAT-VP3融合蛋白进入膀胱癌EJ细胞核内;经该融合蛋白作用后,EJ细胞凋亡率呈时间和剂量依赖关系,细胞周期随着药物作用浓度和时间的增加而改变,EJ细胞的生长抑制率随其浓度的增加和作用时间的延长而呈明显上升趋势。结论改良型TAT-VP3融合蛋白对膀胱癌EJ细胞的增殖具有一定的抑制作用,并对该细胞具有凋亡诱导作用。

Objective To investigate the effect of the improved TAT-VP3 fusion protein on human bladder cancer EJ cell line,and provide experimental basis for its clinical application of tumor biological macromolecules.Methods Immunocytochemical staining was used to confirm the improved TAT-VP3 fusion protein in the nucleus of bladder cancer EJ cells.The inhibition rate of cell growth was detected using the method of CCK-8.Ultrastructural changes of apoptotic cells were observed by transmission electron microscope.Cell cycle and apoptosis were detected by flow cytometry.Results The improved TAT-VP3 fusion protein was in the nucleus of bladder cancer EJ cells,which had a time-and dose-dependent effect on the EJ cells apoptosis.The cell cycle changed with the increased drug concentration.The growth inhibition rate of EJ cells increased with the concentration rising and time going.Conclusion Improved TAT-VP3 fusion protein can inhibit the proliferation of human bladder cancer EJ cells in a certain,and induce apoptosis of the cells as well.